Pricing Log in Create free account

KARDIGAN INC (KARD) vs Taysha Gene Therapies, Inc. (TSHA)

KARDIGAN INC and Taysha Gene Therapies, Inc. are both Biotechnology companies. KARDIGAN INC and Taysha Gene Therapies, Inc. are of similar size ($1.3B and $1.3B). Across the 10 metrics below, KARDIGAN INC leads on 5 and Taysha Gene Therapies, Inc. on 5.

Valuation

Metric KARD TSHA Biotechnology median
P/E n/m n/m 10.60
P/S n/m 136.10 9.40
P/B 0.63 4.15 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.82 n/m 0.66
EV/Sales n/m 101.67 9.02
Earnings yield (95.11%) (9.66%) (32.88%)
Free cash flow yield (43.18%) (8.66%) (23.13%)

Profitability

Metric KARD TSHA Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (47.05%) (51.96%)
Return on assets 0.00% (37.23%) (46.06%)
Return on invested capital (908.80%) 0.00% 0.00%

Growth

Metric KARD TSHA Biotechnology median
Revenue growth (TTM) — 18.96% 6.76%
EPS growth (last fiscal year) (68.79%) 5.56% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KARD TSHA Biotechnology median
Debt to equity 0.00 0.13 0.00
Current ratio 8.72 17.76 4.97
Net debt to EBITDA 1.70 2.47 1.01

Dividend

Metric KARD TSHA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KARD TSHA Biotechnology median
Market cap 1.30b 1.33b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack